Search

Displaying results 4261 - 4270 of 10000 in total
  1. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.

  2. Drug

    Sulfamoxole

    go.drugbank.com/drugs/DB08798
    Experimental

    Sulfamoxole is an antibacterial in the sulfonamide class.

    Synonyms: N(sup 1)-(4,5-Dimethyl-2-oxazolyl)sulfanilamide, 4-Amino-N-(4,5-dimethyl-2-oxazolyl)benzenesulfonamide
  3. Drug

    Dimethylcurcumin

    go.drugbank.com/drugs/DB06133
    Investigational

    Dimethylcurcumin is a synthetic chemical compound that is loosely based on a compound found in curcumin. It is a novel anti-androgen that enhances androgen receptor degradation.

  4. Drug

    Vapendavir

    go.drugbank.com/drugs/DB05181
    Investigational

    BTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and Chronic Obstructive Pulmonary Disease.

  5. Drug

    Afimetoran

    go.drugbank.com/drugs/DB16580
    Investigational

    Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. … [L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male

  6. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

  7. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  8. Drug

    Epicriptine

    go.drugbank.com/drugs/DB11275
    Approved

    Epicriptine is also known as beta-dihydroergocryptine presents a molecular formula of 9,10 alpha-dihydro-13'-epi-b-ergocryptine. … Epicriptine differs from the alpha form on the position of one methyl group.[T195] To know more about the mixture please visit [DB01049]

  9. Drug

    PA-1050040

    go.drugbank.com/drugs/DB06039
    Experimental

    PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.

  10. Drug

    Mitumomab

    go.drugbank.com/drugs/DB06462
    Experimental

    Mitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.